ESR1: Development and validation of improved hiPSC CM assays to study cardiac safety

  • Host organisation: NCARDIA BV (NCAR), the Netherlands
  • PhD-enrolment: Maastricht University, the Nederlands
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: Maastricht University, the Nederlands (3 months)
  • Non-academic secondment: UCB BIOPHARMA SRL, Belgium (3 months)

ESR2: Development and validation of cardiomyocyte model as a predictive assay to assess functional and structural cardiac liabilities

  • Host organisation: UCB BIOPHARMA SRL, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: University of Antwerp, Belgium (3 months)
  • Non-academic secondment: IMEC, Belgium (3 months)

ESR3: Empowering predictivity and speed of hiPSC CM assays by machine learning approach

  • Host organisation: NOTOCORD SYSTEMS, France
  • PhD-enrolment: Sorbonne Université, France
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: INRIA, France (6 months)
  • Non-academic secondment: UCB BIOPHARMA SRL, Belgium (3 months)

ESR4: Development of novel telemetry implants with added 3D micro-GPS functionality

  • Host organisation: TSE SYSTEMS GMBH, Germany
  • PhD-enrolment: TBC, Germany
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: Weizmann Institute of Science, Israel (3 months)
  • Non-academic secondment: Boehringer Ingelheim Pharma GMBH &CO KG, Germany (1 month + 3 months)

ESR5: Extending NOTOCORD-SenseTM with behavioural analysers to enable neuro-cardiovascular assessment in a cloud-based architecture

  • Host organisation: NOTOCORD SYSTEMS, France
  • PhD-enrolment: Sorbonne Université, France
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: Weizmann Institute of Science, Israel (1 month)
  • Academic secondment: INRIA, France (3 months)
  • Non-academic secondment: Boehringer Ingelheim Pharma GMBH &CO KG, Germany (1 month)

ESR6: Development of new algorithms and software to analyse and quantify social interactions and behaviour

  • Host organisation: Weizmann Institute of Science, Israel
  • PhD-enrolment: Weizmann Institute of Science, Israel
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Non-academic secondment: Boehringer Ingelheim Pharma GMBH &CO KG, Germany (1 month)
  • Non-academic secondment: TSE SYSTEMS GMBH, Germany (3 months)

ESR7: Validation and use of novel telemetry implants with 3D micro-GPS functionality for integrated neuro-cardiovascular assessment

  • Host organisation: Boehringer Ingelheim Pharma GMBH &CO KG, Germany
  • PhD-enrolment: TBC, Germany
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: Weizmann Institute of Science, Israel (2 months)
  • Non-academic secondment: TSE SYSTEMS GMBH, Germany (3 months)

ESR8: An in silico approach to monitor and predict haemodynamics during safety pharmacology studies

  • Host organisation: INRIA, France
  • PhD-enrolment: Sorbonne Université, France
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: University of Antwerp, Belgium (2 months)
  • Non-academic secondment: NOTOCORD SYSTEMS, France (3 months)

ESR9: Development of mass spectrometry imaging tools to study drug distribution and associated tissue-specific effects

  • Host organisation: Maastricht University, the Nederlands
  • PhD-enrolment: Maastricht University, the Nederlands
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: University of Antwerp, Belgium (2 months)
  • Non-academic secondment: NCARDIA BV (NCAR), the Netherlands (1 month)

ESR10: Measuring arterial stiffness at different scales: a new toolbox for safety pharmacology

  • Host organisation: University of Antwerp, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: University of Nottingham, the UK (3 months)
  • Non-academic secondment: Vivonics Preclinical Limited, the UK (1 month)

ESR11: New pre-clinical screens in safety pharmacology

  • Host organisation: University of Nottingham, the UK
  • PhD-enrolment: University of Nottingham, the UK
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Non-academic secondment: Vivonics Preclinical Limited, the UK (1 month + 6 months)
  • Non-academic secondment: AstraZeneca UK Limited, the UK (1 week)

ESR12: Assessing the cardiovascular safety liabilities of growth factor inhibition

  • Host organisation: University of Nottingham, the UK
  • PhD-enrolment: University of Nottingham, the UK
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Non-academic secondment: INRIA, France (2 months)
  • Non-academic secondment: AstraZeneca UK Limited, the UK (3 months)

ESR13: Development of novel strategies to mitigate cardio-toxicity and heart failure

  • Host organisation: University of Antwerp, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Non-academic secondment: Antwerp University Hospital, Belgium (2 months)
  • Non-academic secondment: UCB BIOPHARMA SRL, Belgium (3 months)

ESR14: Chemotherapy-induced functional myocardial alterations: is a HFpEF stage preceding HFrEF?

  • Host organisation: University of Antwerp, Belgium
  • PhD-enrolment: University of Antwerp, Belgium
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Academic secondment: Maastricht University, the Nederlands (2 months)
  • Non-academic secondment: IMEC, Belgium (7 months)

ESR15: Personalized SP against drug-evoked proarrhythmia

  • Host organisation: Maastricht University, the Nederlands
  • PhD-enrolment: Maastricht University, the Nederlands
  • Duration: 36 months
  • Expexted start date: ~June 2020
  • Non-academic secondment: NCARDIA BV (NCAR), the Netherlands (3 months)
  • Non-academic secondment: IMEC, Belgium (3 months)